Treatments for autoimmune diseases and those in orphan markets are on the up and up, as are drugmakers’ first launches, ...
New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...
Zacks Investment Research on MSN3d
GSK Stock Recovers, Rises Around 17% YTD: Time to Buy, Sell or Hold?GSK GSK stock has risen 16.9% year to date compared with an increase of 7.0% for the industry. The stock has also ...
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today ...
GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer (PFE) and Shionogi (SGIOY) as ...
Zacks.com on MSN16d
Glaxo (GSK) Up 8% Since Last Earnings Report: Can It Continue?HIV sales rose 14% driven by strong demand and increased market share for oral two-drug regimens, Dovato and Juluca, and long-acting regimens like Cabenuva and Apretude. GSK generates the majority ...
About Cabenuva (cabotegravir + rilpivirine ... is a global specialist HIV company established in November 2009 by GSK (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in ...
LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and ... physician experience we have with Cabenuva and pioneering the next generation ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback